Initial results from AQUARiUS, a prospective, observational, multi-centre phase IV study assessing patient-reported outcomes (PROs) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate plus prednisone (AAP) or enzalutamide (ENZ)

Initial results from AQUARiUS, a prospective, observational, multi-centre phase IV study assessing patient-reported outcomes (PROs) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate plus prednisone (AAP) or enzalutamide (ENZ)

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 28; pp. v287 - v288
Main Authors: Thiery-Vuillemin, A., Poulsen, M.H., Reid, A., Lagneau, E., Ploussard, G., Birtle, A., Dourthe, L.M., Beal-Ardisson, D., Pintus, E., Trepiakas, R., Lukac, M., Van Sanden, S., Dearden, L.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-09-2017
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdx370.046